Annual report pursuant to Section 13 and 15(d)

License and Collaboration Agreements (Details)

v3.22.0.1
License and Collaboration Agreements (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenues     $ 23,404 $ 14,667 $ 6,620 $ 914 $ 50,030 $ 29 $ 29 $ 30 $ 45,605 $ 50,118 $ 318
Thunderbolt                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Upfront payment                       $ 750  
License Agreement Terms | Otuska                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Upfront payments received   $ 50,000                 $ 0    
Potential regulatory milestone revenue   50,000                      
Revenues   $ 50,000                      
License Agreement Terms | Otuska | Minimum                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Tiered royalty percentages on future sales   10.00%                      
License Agreement Terms | Otuska | Maximum                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Tiered royalty percentages on future sales   20.00%                      
License Agreement Terms | Riptide Bioscience, Inc.                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Payments to acquire productive assets $ 6,000